Professional Documents
Culture Documents
Outline
Diagnosing ADHD
Treatment Recommendations
Psychopharmacological Interventions
Stimulants
PSYCHOPHARMACOLOGICAL
TREATMENT OF ADHD AND
COMMON CO-MORBID DISORDERS
and Non-Stimulants
Treatment Strategies
Case Studies
DSM Definition
Diagnosing ADHD
Inattentive Symptoms
18 official symptoms
6/9 symptoms of inattentiveness or hyperactivity/impulsivity for
under 17 yo, only 5 in 17yo and older
Lasting at least 6 months
Maladaptive and exceeding norm for age
Begins prior to age 12
Causes clinically significant impairment in two or more settings
Not better accounted for by another disorder
Hyperactive/Impulsive Symptoms
Hyperactivity
Fidgets
Leaves seat when expected
to remain seated
Runs or climbs excessively
Difficulty playing or
engaging in leisure activities
quietly
Often on the go or acts as
if driven by a motor
Talks excessively
Impulsivity
2/18/2015
Differential Diagnosis
Depression
Bipolar Disorder
ODD/ CD
Substance Use
Intellectual Disability
Typical development
Phobias
Worries
Stress induced onset
Obsessions
Compulsions
Perfectionism
Somatic complaints
Posttraumatic play
Hyperthyroidism
Seizures
Lead toxicity
Food or food additive sensitivity
Sleep apnea
Substance abuse
Depressed mood
Anorexia/ Weight loss
SI
Excessive Guilt
Psychomotor retardation
Mutism
Fatigue
Episodic
Grandiosity
Pressured speech
Racing thoughts
Nearly
So
continuous need for 1 or more less hours per night than avg child without feeling tired
Unintelligible,
2/18/2015
Treatment
Fantasy
play
relatedness
Imaginative play
Social
Treatment Guidelines
Follow-Up to MTA
579
Neurochemical Factors
Psychopharmacological
Interventions
Dopamine
Verbal fluency
Serial learning
Vigilance for executive
functioning
Sustaining and focusing
attention
Prioritizing behavior
Modulating behavior based
on social cues
Norepinephrine
2/18/2015
19
Increase in norepinephrine
increases strength of signals to the prefrontal
cortex
Increase in dopamine
increase in saliency, decreases noise from
extraneous stimuli
Stimulants
Non-Stimulants
Methylphenidates
Atomoxetine
Amphetamines
Alpha-2
(Strattera)
Agonists
Bupropion (Wellbutrin)
TCAs
Modafinil (Provigil)
Stimulants
Stimulants
Stimulant Medications
Methylphenidates
Methylphenidate
Ritalin
Methylin
Focalin
Ritalin SR
Amphetamines
Amphetamine/ dextroamphetamine
Adderall
Dexedrine
Dexedrine Spansules
Metadate ER
Dextro Stat
Methylin SR
Adderall XR
Ritalin LA
Vyvanse
Metdate CD
Focalin XR
Daytrana
Quillivant XR
Concerta
l-amphetamine
Similar
2/18/2015
Behavioral
IR Methylphenidate Dosing
Focalin
Ritalin LA
BID
Often need immediate release in morning to compensate
Start 2.5 mg
Increase q 7 days
Max: 20 mg total daily dose
Focalin XR
2/18/2015
Metadate CD
Ages
6-15
as immediate release and 70% delayed release
Peaks 1-2 and 4-5
6-8 hours duration
Start: 10 mg po q am
Max: 60 mg po q am
Methylphenidate ER (Concerta)
to immediate release
Apply
Plasma
Quillivant XR
methylphenidate ER oral solution
ages 6 and older
initial dose: 20 mg once a day
max dose: 60 mg once a day
may increase daily dose by 10-20 mg at weekly
intervals
Long-Acting Amphetamine
IR Amphetamines
Complex-release formulation
30%
Dual pulse with 1/2 immediate- and extended- release beads (just
like Ritalin LA and Focalin XR)
6-8 hours duration
Peak in 7 hours
Start 5 or 10 mg q am
Increase by 5-10 mg/day at weekly intervals as needed
Max typically 30 mg daily
Peaks in 4 hours
6-8 hours duration
Max 60 mg po q am
2/18/2015
Prodrug of Dextroamphetamine
Sudden death
Angina
Tachycardia
Palpitations
HTN
Seizures
Appetite suppression
Absorption and bioavailability may increase after meal
Immediate release
Capsules
Height/ Weight
BP
HR
Rating Scales
Stimulant Nonresponders
Pt factors:
Is
it really ADHD?
there a comorbid diagnosis?
Are side effects interfering w response?
Is the patient compliant?
Is
Irritability
Aggression
Depressed mood
Medication factors:
Is
2/18/2015
Stimulant Nonresponders
Family Factors:
Nonstimulants
Are
Nonstimulants
Monotherapy
Adjunct treatment
Atomoxetine (Strattera)
Atomoxetine (Strattera)
Dosing:
Drug interactions:
Not within 14 days of MAOIs
Decrease dose of atomoxetine with CYP450 2D6 inhibitors
(fluoxetine and paroxetine)
Co-administration with albuterol may increase HR and BP
2 FDA warnings:
Side effects:
2/18/2015
Atomoxetine
Wait
dose
dose
Change medication
Split
and wt
BP and pulse
Monitor:
Ht
Lower
Aggression
Hyperactivity
Hyperarousal (anxiety/ PTSD)
Impulsivity
Sleep disturbance
Only 10 children
Results: reduction in hyperactivity and aggression
Dosing:
Clonidine (Catapres)
Guanfacine (Tenex)
1 mg strength
Start tab at bedtime
May increase by 0.5 mg q 4-6 days
Max typically 3 mg total daily dosing
Dose TID
less sedating than clonidine
2/18/2015
Guanfacine XR (Intuniv)
345/324
weeks
Double-blind, placebo-controlled, parallel-group, fixed
dose design
Increased by 1 mg/week
No patients under 55 lbs
8/9
Guanfacine XR (Intuniv)
Side Effects:
sedation,
Caution:
Documented
Monitoring
BP,
pulse
10
2/18/2015
Buproprion (Wellbutrin)
Some studies have found comparable effects but more dropouts with IMI vs
Methylphenidate (Rapoport et al., 1974; Werry et al., 1980)
Modafinil (Provigil)
65
Nortriptyline (Pamelor)
Buproprion (Wellbutrin)
Stimulants
Adderall XR
Vyvanse
Quillivant XR
Focalin XR
Concerta
Non-Stimulant
Strattera
Treatment Strategies
11
2/18/2015
AACAP practice parameters for ADHD (Plizka and AACAP Work Group
on Quality Issues 2007)
An international consensus statement (Kuthcher et al., 2004)
American Academy of Pediatrics (2001)
The Texas Childrens Medication Algorithm Project: Revision of the
Algorithm for Phamacotherapy of ADHD (Plizka et al., 2006)
Stage 0:
Diagnostic assessment
Non medication treatment alternatives
Stage 4:
Stage 5:
Stage 3:
Exogenous Melatonin
Methylphenidate or Amphetamine
Atomoxetine
Bupropion or TCA
Alpha-2 agonists
Clondine up to 0.2 mg q hs
Tenex up to 2 mg q hs
Partial response
Breakthrough symptoms
Mirtazapine (Remeron)
Trazodone (Desyrel)
Benadryl 25-50 mg
Hydroxyzine (Vistaril)
Anticholinergic SEs
OTC
Natural hormone that regulates circadian rhythms
As a drug can synchronize circadian clock to environmental cycle
1.5-9 mg at bedtime
Antihistamine
Stage 6:
Anxiety
MDD
Tic Disorder
Aggression
Stage 2:
Stage 1:
Algorithms
Rebound Symptoms
alpha 2 agonists
another dose of stimulant
12
2/18/2015
2/3 of children with ADHD also meet criteria for other psychiatric
disorders
50% have ODD or CD
50% have learning disorders
25-30% have an anxiety disorders
2% have Tourettes
Target sxs
SEs
Taking as prescribed
Missed doses
Much higher with ADHD than random population sample or with other
disorders
Tic
disoder
aggression
http://www.dshs.state.tx.us/mhprograms/adhdpage.
shtm
13
2/18/2015
Case Study #1
Case Studies
Ritalin
Case Study #2
Case Study #3
14
2/18/2015
Case Study #4
Pt is an 11 yo ca f seen for f/u for ADHD and adjustment d/o r/t family discord,
neglect and variable involvement of bio-mom.
Current Meds:
Tenex 0.5 mg TID
Concerta 18 mg
Pt has been taking Concerta 18 mg X 2 weeks. GM reports that pt c/o chest pain,
agitation, nervousness, "not feeling like herself" and anger on Concerta. GM reports
that pt was given EKG by PCP due to c/o chest pain on Vyvanse and it was wnl. No
reports of syncope. Vital signs wnl.
She continues to be hyperactive, impulsive and defiant. This is problematic at home,
school and church. Current wt. 132 lbs, 60 kg
Past medication trials:
Vyvanse
Adderall XR
Concerta
Focalin XR
Pt c/o several SEs on all stimulants.
References
Barkley, Russell A (2000). Taking Charge of ADHD: The complete, authoritative guide for parents
(Revised ed.). New York: Guildord Press.
Barkley R, Murphey K (2005). Attention-Deficit Hyperactivity Disorder: A Clinical Workbook. New
York: Guliford Press. .
Findling, Robert L. (2008). Clinical Manuel of Child and Adolescent Psychopharmacology (4th ed.).
Arlington: American Psychiatric Publishing, Inc.
Green, Wayne H. (2007). Child and Adolescent Clinical Psychopharmacology. Philadelphia:
Lippincott, Williams and Wilkins.
Kolevzon A, Stewart D (2004). Psychiatry Pearls: The Pearls Series. United States: Hanley & Belfus,
Inc.
Lewis (2007). Lewiss Child and Adolescent Psychiatry: A Comprehensive Textbook (4th ed.).
Philadelphia: Lippincott, Williams and Wilkins.
Sadock B, Sadock V. (2003). Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry (9th ed.).
Philadelphia: Lippincott, Williams and Wilkins.
Stahl, Stephen M. (2000). Essential Psychopharmacology: Neuroscientific Basis and Practical
Applications (2nd ed.). Cambridge: Cambridge University Press. S
Stahl, Stephen M. (2008). Everything You Wanted to Know About ADHD But Forgot You Wanted to
Ask. Carlsbad, California: NEI Press.
The End
15